Takara Bio Inc. (JP:4974) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Takara Bio Inc. showcased mixed financial performance in its 22nd term, with net sales dropping to 43,505 million yen from the previous year’s 78,142 million yen, and a significant decline in profit attributable to owners of the parent to 1,480 million yen, compared to 16,012 million yen in the 21st term. Despite these downturns, the company has maintained a robust shareholders’ equity ratio of 92% and continued to invest heavily in research and development, especially in its Reagents and Instruments business and CDMO services for regenerative medicine and gene/cell therapy, accounting for 19.1% of net sales.
For further insights into JP:4974 stock, check out TipRanks’ Stock Analysis page.